API Corp. Invests in Neuland for More API, Intermediate Manufacturing

Related tags Active ingredient

API Corp. Invests in Neuland for More API, Intermediate Manufacturing
Tokyo-based API Corporation, a unit of Mitsubishi Chemical Holdings Group, is making an investment in API and pharmaceutical manufacturer Neuland Laboratories’ facilities.

The undisclosed investment “will be specifically used for dedicated capacity within Neuland for the manufacture of certain intermediates and APIs exclusively for APIC and its customers​,” Saharsh R. Davuluri, President of Contract Research at Neuland, told in-Pharmatechnologist.com.

The facilities will be operated by Neuland employees and the two companies will share oversight and management responsibilities.

This agreement between Neuland and APIC is an outstanding example of a win-win collaboration between companies that share many values and are complementary in terms of capabilities and markets served​,” Dr. D.R. Rao, chairman and managing director of Neuland said.

Neuland also pledges to independently expand its business in Japan, building on its customer base for both generic API manufacturing and contract manufacturing of APIs and intermediates.

Specifically, Neuland first started manufacturing pharmaceutical ingredients for Japanese customers in 2003​,” Davuluri said, noting that the company established a fully-owned subsidiary in Japan in 2007 and in recent years opened an office in Tokyo. 

Neuland supplies APIs and intermediates to both Japanese generic manufacturers and those selling NCEs. It is working to identify additional customers who require reliable partners to produce APIs and intermediates.  “Neuland believes there is significant demand in Japan for the high quality products it has been delivering to customers worldwide for almost 30 years​,” Davuluri added.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars